Resistance mutation info of drug
| Drug General Information | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D04XVN | ||||||||||||||
| Drug Name | Trametinib | ||||||||||||||
| Synonyms | GSK 1120212; GSK-1120212; GSK1120212; JTP 74057; JTP-74057; Mekinist; Trametinib (GSK1120212); Trametinib (GSK1120212JTP 74057); Trametinib (MEK inhibitor); 33E86K87QN; A1-01871; AK174783; CHEBI:75998; UNII-33E86K87QN | ||||||||||||||
| Drug Type | Small molecular drug | ||||||||||||||
| Company | GlaxoSmithKline | ||||||||||||||
| Structure |
|
||||||||||||||
| Drug Resistance Mutations | |||||||||||||||
| Target Name | Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) | Target Info | |||||||||||||
| Gene Name | MAP2K2 | ||||||||||||||
| Uniprot ID | MP2K2_HUMAN | ||||||||||||||
| Species | Homo sapiens | ||||||||||||||
| Reference Sequence |
MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV [Homo sapiens] |
||||||||||||||
| Targeted Disease | Skin cancer | ||||||||||||||
| Drug Resistance Mutations |
|
||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
| References | |||||||||||||||
| REF 1 | The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan;4(1):94-109. | ||||||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.